{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T11:06:41Z","timestamp":1779361601412,"version":"3.51.4"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"DOI":"10.1186\/s12913-026-14468-4","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T01:43:54Z","timestamp":1775785434000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hyperkalemia management in heart failure and chronic kidney disease: a Spanish cost-effectiveness analysis of patiromer informed by the integrated DIAMOND trial and real-world evidence"],"prefix":"10.1186","volume":"26","author":[{"given":"A.","family":"Bayes-Genis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Butler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Stawowczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. D.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. T.","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Ramirez de Arellano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"14468_CR1","doi-asserted-by":"publisher","unstructured":"Rosano GMC, et al. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology, (in eng). Eur Heart J Cardiovasc Pharmacother. 2018 Jul 1;4(3):180\u201388. https:\/\/doi.org\/10.1093\/ehjcvp\/pvy015.","DOI":"10.1093\/ehjcvp\/pvy015"},{"key":"14468_CR2","doi-asserted-by":"publisher","unstructured":"Thomsen RW, et al. Elevated potassium levels in patients with congestive heart failure: occurrence, risk factors, and clinical outcomes: a Danish population-based cohort study, (in eng). J Am Heart Assoc. 2018 May 22;7(11). https:\/\/doi.org\/10.1161\/jaha.118.008912.","DOI":"10.1161\/jaha.118.008912"},{"key":"14468_CR3","doi-asserted-by":"publisher","unstructured":"Damman K, Valente MA, Voors AA, O\u2019Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis, (in eng). Eur Heart J. 2014 Feb;35(7):455\u201369. https:\/\/doi.org\/10.1093\/eurheartj\/eht386.","DOI":"10.1093\/eurheartj\/eht386"},{"key":"14468_CR4","doi-asserted-by":"publisher","unstructured":"Ferreira JP, et al. Serum potassium in the PARADIGM-HF trial. Eur J Heart Fail. 2020 Nov;22(11):2056\u201364. https:\/\/doi.org\/10.1002\/ejhf.1987.","DOI":"10.1002\/ejhf.1987"},{"key":"14468_CR5","doi-asserted-by":"publisher","unstructured":"Silva-Cardoso J, et al. Management of RAASi-associated hyperkalemia in patients with cardiovascular disease. Heart Fail Rev. 2021 Jul;26(4):891\u20136. https:\/\/doi.org\/10.1007\/s10741-020-10069-3.","DOI":"10.1007\/s10741-020-10069-3"},{"key":"14468_CR6","doi-asserted-by":"publisher","unstructured":"Palmer BF, Clegg DJ. Pathophysiology and clinical management of hyperkalemia in chronic kidney disease. Minerva Med. 2023 Mar;13. https:\/\/doi.org\/10.23736\/S0026-4806.23.08465-3.","DOI":"10.23736\/S0026-4806.23.08465-3"},{"key":"14468_CR7","doi-asserted-by":"publisher","unstructured":"Anker SD, et al. Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial, (in eng). Eur J Heart Fail. 2015 Oct;17(10):1050\u20136. https:\/\/doi.org\/10.1002\/ejhf.300.","DOI":"10.1002\/ejhf.300"},{"key":"14468_CR8","doi-asserted-by":"publisher","unstructured":"Pitt B, Anker SD, Bushinsky DA, Kitzman DW, Zannad F, Huang IZ. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial, (in eng). Eur Heart J. 2011 Apr;32(7):820\u20138. https:\/\/doi.org\/10.1093\/eurheartj\/ehq502.","DOI":"10.1093\/eurheartj\/ehq502"},{"key":"14468_CR9","doi-asserted-by":"publisher","unstructured":"Trevisan M, et al. Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care, (in eng). Eur J Heart Fail. 2021 Oct;23(10):1698\u2013707. https:\/\/doi.org\/10.1002\/ejhf.2287.","DOI":"10.1002\/ejhf.2287"},{"key":"14468_CR10","doi-asserted-by":"publisher","unstructured":"Xu Y, et al. Stopping renin-angiotensin system inhibitors after hyperkalemia and risk of adverse outcomes, (in eng). Am Heart J. 2022 Jan;243:177\u201386. https:\/\/doi.org\/10.1016\/j.ahj.2021.09.014.","DOI":"10.1016\/j.ahj.2021.09.014"},{"key":"14468_CR11","doi-asserted-by":"publisher","unstructured":"Cobo Marcos M, et al. Prevalence and clinical profile of kidney disease in patients with chronic heart failure. Insights from the Spanish cardiorenal registry, (in eng spa). Rev Esp Cardiol (Engl Ed). 2024 Jan;77(1):50\u20139. https:\/\/doi.org\/10.1016\/j.rec.2023.05.003.","DOI":"10.1016\/j.rec.2023.05.003"},{"key":"14468_CR12","doi-asserted-by":"crossref","unstructured":"Anguita S\u00e1nchez M, Crespo Leiro MG, de Teresa Galv\u00e1n E, Jim\u00e9nez Navarro M, Alonso-Pulp\u00f3n L, Mu\u00f1iz Garc\u00eda J. Prevalence of heart failure in the Spanish general population aged over 45 years. The PRICE Study, (in eng). Rev Esp Cardiol. 2008 Oct;61(10):1041\u20139. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1885585709600074.","DOI":"10.1016\/S1885-5857(09)60007-4"},{"key":"14468_CR13","unstructured":"H. F. P. Network. Heart failure policy and practice in Europe: Spain. https:\/\/www.hfpolicynetwork.org\/wp-content\/uploads\/Heart-failure-policy-and-practice-in-Europe-Spain.pdf. (accessed 15\/01\/2025, 2025)."},{"key":"14468_CR14","doi-asserted-by":"publisher","unstructured":"Sayago-Silva I, Garc\u00eda-L\u00f3pez F, Segovia-Cubero J. Epidemiology of heart failure in Spain over the last 20 years, (in eng). Rev Esp Cardiol (Engl Ed). 2013Aug;66(8):649\u201356. https:\/\/doi.org\/10.1016\/j.rec.2013.03.012.","DOI":"10.1016\/j.rec.2013.03.012"},{"key":"14468_CR15","doi-asserted-by":"publisher","unstructured":"Conde-Martel A, Hern\u00e1ndez-Meneses M. Prevalence and prognostic meaning of comorbidity in heart failure, (in spa). Rev Clin Esp (Barc). 2016 May;216(4):222-8. https:\/\/doi.org\/10.1016\/j.rce.2015.08.005. Prevalencia y significado pron\u00f3stico de la comorbilidad en la insuficiencia cardiaca.","DOI":"10.1016\/j.rce.2015.08.005"},{"key":"14468_CR16","doi-asserted-by":"publisher","unstructured":"Linde C, et al. Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UK, (in eng). ESC Heart Fail. 2019 Apr;6(2):280\u201390. https:\/\/doi.org\/10.1002\/ehf2.12402.","DOI":"10.1002\/ehf2.12402"},{"key":"14468_CR17","doi-asserted-by":"publisher","unstructured":"Almenar Bonet L, Gonz\u00e1lez-Franco \u00c1. Consensus on the management of hyperkalemia in patients with heart failure: recommendations from the SEC-SEMI, (in eng). Rev Clin Esp (Barc). 2022 Apr;222(4):235\u201340. https:\/\/doi.org\/10.1016\/j.rceng.2020.11.012.","DOI":"10.1016\/j.rceng.2020.11.012"},{"key":"14468_CR18","doi-asserted-by":"publisher","unstructured":"Ponikowski P, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC, (in eng). Eur J Heart Fail. 2016 Aug;18(8):891\u2013975. https:\/\/doi.org\/10.1002\/ejhf.592.","DOI":"10.1002\/ejhf.592"},{"key":"14468_CR19","doi-asserted-by":"publisher","unstructured":"KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease, (in eng). Kidney Int. 2020 Oct;98(4s):S1-s115. https:\/\/doi.org\/10.1016\/j.kint.2020.06.019.","DOI":"10.1016\/j.kint.2020.06.019"},{"key":"14468_CR20","doi-asserted-by":"publisher","unstructured":"KDIGO 2021 Clinical practice guideline for the management of blood pressure in chronic kidney disease, (in eng). Kidney Int. 2021 Mar;99(3s):S1-s87. https:\/\/doi.org\/10.1016\/j.kint.2020.11.003.","DOI":"10.1016\/j.kint.2020.11.003"},{"key":"14468_CR21","doi-asserted-by":"publisher","unstructured":"Rossignol P, David L, Chan C, Conrad A, Weir MR. Safety and tolerability of the potassium binder patiromer from a global pharmacovigilance database collected over 4 years compared with data from the clinical trial program, (in eng). Drugs Real World Outcomes. 2021 Sep;8(3):315\u201323. https:\/\/doi.org\/10.1007\/s40801-021-00254-7.","DOI":"10.1007\/s40801-021-00254-7"},{"key":"14468_CR22","doi-asserted-by":"publisher","unstructured":"Esteban-Fern\u00e1ndez A, et al. Experience with the potassium binder patiromer in hyperkalaemia management in heart failure patients in real life, (in eng). ESC Heart Fail. 2022 Oct;9(5):3071\u20138. https:\/\/doi.org\/10.1002\/ehf2.13976.","DOI":"10.1002\/ehf2.13976"},{"key":"14468_CR23","doi-asserted-by":"publisher","unstructured":"Butler J, et al. Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial, (in eng). Eur Heart J. 2022 Nov 1;43:4362\u201373. https:\/\/doi.org\/10.1093\/eurheartj\/ehac401.","DOI":"10.1093\/eurheartj\/ehac401"},{"key":"14468_CR24","doi-asserted-by":"publisher","unstructured":"Pitt B, et al. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors, (in eng). Eur J Heart Fail. 2015 Oct;17(10):1057\u201365. https:\/\/doi.org\/10.1002\/ejhf.402.","DOI":"10.1002\/ejhf.402"},{"key":"14468_CR25","doi-asserted-by":"publisher","unstructured":"Ward T, Brown T, Lewis RD, Kliess MK, de Arellano AR, Quinn CM. The cost effectiveness of patiromer for the treatment of hyperkalaemia in patients with chronic kidney disease with and without heart failure in Ireland, (in eng). Pharmacoecon Open. 2022 Sep;6(5):757\u2013771. https:\/\/doi.org\/10.1007\/s41669-022-00357-z.","DOI":"10.1007\/s41669-022-00357-z"},{"key":"14468_CR26","doi-asserted-by":"publisher","unstructured":"Ward T, Lewis RD, Brown T, Baxter G, de Arellano AR. A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure. (in eng) BMC Nephrol. 2023 Mar 9;24(1):47. https:\/\/doi.org\/10.1186\/s12882-023-03088-3.","DOI":"10.1186\/s12882-023-03088-3"},{"key":"14468_CR27","doi-asserted-by":"publisher","unstructured":"Wid\u00e9n J, et al. Cost-effectiveness analysis of patiromer in combination with renin-angiotensin-aldosterone system inhibitors for chronic kidney disease in Sweden, (in eng). Pharmacoeconomics. 2020 Jul;38(7):747\u201364. https:\/\/doi.org\/10.1007\/s40273-020-00902-w.","DOI":"10.1007\/s40273-020-00902-w"},{"key":"14468_CR28","doi-asserted-by":"publisher","unstructured":"Gonz\u00e1lez-Juanatey JR, et al. A cost-effectiveness analysis of patiromer for the treatment of hyperkalemia in chronic kidney disease patients with and without heart failure in Spain, (in eng). J Med Econ. 2022 Jan-Dec;25(1):640\u20139. https:\/\/doi.org\/10.1080\/13696998.2022.2074193.","DOI":"10.1080\/13696998.2022.2074193"},{"key":"14468_CR29","doi-asserted-by":"publisher","unstructured":"Butler J, et al. Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial, (in eng). Eur J Heart Fail. 2022 Jan;24(1):230\u20138. https:\/\/doi.org\/10.1002\/ejhf.2386.","DOI":"10.1002\/ejhf.2386"},{"key":"14468_CR30","doi-asserted-by":"publisher","unstructured":"Senni M, Paoletti E, Stawowczyk E, Hale M, de Arellano AR. Economic evaluation of patiromer in patients with concomitant heart failure and chronic kidney disease in Italy, (in eng). Pharmacoecon Open. 2025 Jul;9(4):693\u201306. https:\/\/doi.org\/10.1007\/s41669-025-00581-3.","DOI":"10.1007\/s41669-025-00581-3"},{"key":"14468_CR31","doi-asserted-by":"publisher","unstructured":"Attema AE, Brouwer WBF, Claxton K. Discounting in economic evaluations, (in eng). Pharmacoeconomics. 2018 Jul;36(7):745\u2013758. https:\/\/doi.org\/10.1007\/s40273-018-0672-z.","DOI":"10.1007\/s40273-018-0672-z"},{"key":"14468_CR32","doi-asserted-by":"publisher","unstructured":"Elbasha E, Greaves W, Roth D, Nwankwo C. Cost-effectiveness of elbasvir\/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States, (in eng). J Viral Hepat. 2017 Apr;24(4):268\u201379. https:\/\/doi.org\/10.1111\/jvh.12639.","DOI":"10.1111\/jvh.12639"},{"key":"14468_CR33","doi-asserted-by":"publisher","unstructured":"Cooper BA, et al. A randomized, controlled trial of early versus late initiation of dialysis, (in eng). N Engl J Med. 2010 Aug 12;363(7):609\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1000552.","DOI":"10.1056\/NEJMoa1000552"},{"key":"14468_CR34","unstructured":"N. B. A. Transport, Annual report on kidney transplantation, 2019."},{"key":"14468_CR35","unstructured":"U. R. Association, UK renal registry 8th annual report, 2004. [Online]. Available: https:\/\/ukkidney.org\/about-us\/who-we-are\/uk-renal-registry."},{"key":"14468_CR36","unstructured":"U. R. Association, UK Renal Registry 23rd annual report 2021, 2021."},{"key":"14468_CR37","doi-asserted-by":"publisher","unstructured":"Karim A, et al. Recipient age and risk for mortality after kidney transplantation in England, (in eng). Transplantation. 2014 Apr 27;97(8):832-8. https:\/\/doi.org\/10.1097\/01.TP.0000438026.03958.7b.","DOI":"10.1097\/01.TP.0000438026.03958.7b"},{"key":"14468_CR38","doi-asserted-by":"publisher","unstructured":"Xie X, et al. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials, (in eng). Am J Kidney Dis. 2016 May;67(5):728\u201341. https:\/\/doi.org\/10.1053\/j.ajkd.2015.10.011.","DOI":"10.1053\/j.ajkd.2015.10.011"},{"key":"14468_CR39","doi-asserted-by":"publisher","unstructured":"Yao G, Freemantle N, Calvert MJ, Bryan S, Daubert JC, Cleland JG. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator, (in eng). Eur Heart J. 2007 Jan;28(1):42\u201351. https:\/\/doi.org\/10.1093\/eurheartj\/ehl382.","DOI":"10.1093\/eurheartj\/ehl382"},{"key":"14468_CR40","unstructured":"Instituto Nacional de Estad\u00cdstica, \"National indices: overall and by ECOICOP group.\" [Online]. Available: https:\/\/www.ine.es\/jaxiT3\/Tabla.htm?t=50902&L=1."},{"key":"14468_CR41","unstructured":"Sodium zirconium cyclosilicate for treating hyperkalaemia, technology appraisal guidance [TA599] [Online] Available: https:\/\/www.nice.org.uk\/guidance\/ta599."},{"key":"14468_CR42","unstructured":"Consejo General de Colegios Oficiales de Farmac\u00e9uticos, \"Portal Farma. BotPLUS. Consejo General de Colegios Oficiales de Farmaceuticos.\" [Online]. Available: https:\/\/botplusweb.farmaceuticos.com\/."},{"key":"14468_CR43","unstructured":"Phillippo D, Ades MAE, Dias S, Palmer S, Abrams K, Welton N. J NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE. [Online]. Available: http:\/\/www.nicedsu.org.uk."},{"key":"14468_CR44","doi-asserted-by":"publisher","unstructured":"Signorovitch JE, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept, (in eng). Pharmacoeconomics. 2010;28(10):935\u201345. https:\/\/doi.org\/10.2165\/11538370-000000000-00000.","DOI":"10.2165\/11538370-000000000-00000"},{"key":"14468_CR45","doi-asserted-by":"publisher","unstructured":"Garcia-Lorenzo B, Vallejo-Torres L, Trujillo-Martin MM, Perestelo-Perez L, Valcarcel-Nazco C, Serrano Aguilar P. Economic evaluation seeks threshold to support decision-making. Rev Esp Salud Publica. 2015 Nov-Dec;89(6):537\u201344. https:\/\/doi.org\/10.4321\/S1135-57272015000600002. Evaluacion economica busca umbral para apoyar la toma de decisiones.","DOI":"10.4321\/S1135-57272015000600002"},{"key":"14468_CR46","unstructured":"Marcos MC, et al. Prevalence and clinical profile of kidney disease in patients with chronic heart failure. Insights from the Spanish cardiorenal registry. Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition). 2023."},{"key":"14468_CR47","doi-asserted-by":"publisher","unstructured":"Escobar C, et al. Costs and healthcare utilisation of patients with heart failure in Spain, (in eng). BMC Health Serv Res. 2020 Oct 20;20(1):964. https:\/\/doi.org\/10.1186\/s12913-020-05828-9.","DOI":"10.1186\/s12913-020-05828-9"},{"key":"14468_CR48","doi-asserted-by":"publisher","unstructured":"Crespo-Leiro MG, et al. Hyperkalemia in heart failure patients in Spain and its impact on guidelines and recommendations: ESC-EORP-HFA Heart Failure Long-Term Registry, (in eng spa). Rev Esp Cardiol (Engl Ed). 2020 Apr;73(4):313\u201323. https:\/\/doi.org\/10.1016\/j.rec.2019.05.015.","DOI":"10.1016\/j.rec.2019.05.015"},{"key":"14468_CR49","doi-asserted-by":"publisher","unstructured":"Maggioni AP, et al. Prevalence, clinical impact and costs of hyperkalaemia: Special focus on heart failure, (in eng). Eur J Clin Invest. 2021 Aug;51(8):e13551. https:\/\/doi.org\/10.1111\/eci.13551.","DOI":"10.1111\/eci.13551"},{"key":"14468_CR50","first-page":"4","volume":"23","author":"M Polson","year":"2017","unstructured":"Polson M, et al. Clinical and economic impact of hyperkalemia in patients with chronic kidney disease and heart failure. J Managed Care Specialty Pharm. 2017;23:4\u2013aSuppl:S2-S9.","journal-title":"J managed care specialty Pharm"},{"key":"14468_CR51","unstructured":"European Medicines Agency. Veltassa EPAR summary for the public, ed, 2017."},{"key":"14468_CR52","doi-asserted-by":"publisher","unstructured":"Grandy S, Jackson J, Moon R, Bluff D, Palaka E. Health-related quality of life and lifestyle changes in patients with chronic kidney disease and hyperkalaemia: real-world data from the US, five European countries and China, (in eng). Int J Clin Pract. 2021 Aug;75(8):e14326. https:\/\/doi.org\/10.1111\/ijcp.14326.","DOI":"10.1111\/ijcp.14326"},{"key":"14468_CR53","doi-asserted-by":"publisher","unstructured":"Olry de Labry A, Lima, et al. Hyperkalaemia management and related costs in chronic kidney disease patients with comorbidities in Spain, (in eng). Clin Kidney J. 2021 Nov;14(11):2391\u2013400. https:\/\/doi.org\/10.1093\/ckj\/sfab076.","DOI":"10.1093\/ckj\/sfab076"},{"key":"14468_CR54","doi-asserted-by":"publisher","unstructured":"Svensson MK, et al. Hyperkalaemia-related reduction of RAASi treatment associates with more subsequent inpatient care, (in eng). Nephrol Dial Transpl. 2024 Jan;22. https:\/\/doi.org\/10.1093\/ndt\/gfae016.","DOI":"10.1093\/ndt\/gfae016"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-026-14468-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-14468-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-14468-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T10:29:04Z","timestamp":1779359344000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12913-026-14468-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["14468"],"URL":"https:\/\/doi.org\/10.1186\/s12913-026-14468-4","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"3 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Early analyses were presented previously at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe; Copenhagen, Denmark; November 12\u201315, 2023.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Previous presentations"}},{"value":"ABG has lectured and participated in advisory boards for Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Medtronic, Roche Diagnostics and Vifor. JB has consulted for Consultant Abbott, Adaptyx, American Regent, Amgen, AskBio, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardiac Dimension, Cardior, CSL Vifor, CVRx, Cytokinetics, Daxor, Diastol, Edwards, Element Sciences, Faraday, Idorsia, Impulse Dynamics, Imbria, Innolife, Intellia, Inventiva, Levator, Lexicon, Eli Lilly, Mankind, Medtronic, Merck, New Amsterdam, Novartis, NovoNordisk, Pfizer, Pharmacosmos, Pharmain, Prolaio, Pulnovo, Regeneron, Renibus, Reprieve, Roche, Rycarma, Saillent, Salamandra, Salubris, SC Pharma, SQ Innovation, Secretome, Sequanna, Transmural, TekkunLev, Tenex, Tricog, Ultromic, Vera, and Zoll. ARdA is an employee of CSL Vifor at the time of original drafts. ES, MT, RL and IL are employees of Health Economics and Outcomes Research Ltd. Health Economics and Outcomes Research Ltd. received fees from CSL Vifor in relation to this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"715"}}